On August 12, 2026, Eli Lilly filed six lawsuits against U.S. businesses it accuses of selling black-market retatrutide, and announced at the same time that it has referred more than 200 individuals and entities to regulators and law enforcement. The filings are:
- Eli Lilly & Co. v. Aesthetic Envy Cosmetic Centers LLC, d/b/a Aesthetic Envy (N.D. Cal.)
- Eli Lilly & Co. v. Astra LLC, d/b/a Astra Peptides (W.D. Tex.)
- Eli Lilly & Co. v. Legendary Peptides, LLC (E.D. Tex.)
- Eli Lilly & Co. v. Striker Pharmacy, LLC (S.D. Tex.)
- Eli Lilly & Co. v. Texas Peptides Inc. (W.D. Tex.)
- Eli Lilly & Co. v. Lone Star Peptide Co. (S.D. Tex.)
I have been telling clients for the better part of a year that if they built a retatrutide offering, the letter that showed up would not be from a state board or a district office. It would be from Lilly''s outside counsel. That is not a hard call to make when you have already watched this company go after the compounding space directly rather than waiting for an agency to move, but it is the opposite of how most operators in this market have been sizing up their risk, and this week is the reason it matters.
Why the manufacturer was always the more likely plaintiff
Retatrutide is an investigational triple-agonist molecule in Phase 3 trials for obesity, type 2 diabetes, and related indications. No regulator anywhere in the world has approved any medicine containing it, and Lilly has said it plans to file for approval in early 2027, with realistic commercial availability well after that.
That means Lilly is currently absorbing the entire cost of proving this molecule works and the entire liability for anything that goes wrong with it. It is funding the trials, enrolling patients, collecting adverse event data, and assembling the file it will eventually hand to the FDA. Every unregulated vial sold under the name retatrutide rides on that investment without contributing to it, and every bad outcome from an unverified product made in an uninspected foreign facility attaches to the same molecule name in the same public conversation, in the window where Lilly is least able to afford it. A company in that position has both the motive and the budget to move on its own schedule, which is why the civil complaint shows up before the enforcement action rather than after it.
Lilly''s own framing is consistent with this. In announcing the filings, chief medical officer David Hyman drew the line between the molecule under study and what is being sold, describing the black-market product as unverified, unapproved, and "not worth the risk." Max Denning, an associate vice president at Lilly, told CBS News the supply chain traces back to overseas manufacturers, and acknowledged that six lawsuits "is not going to be the solution to everything" while framing them as an opening move.
What is actually in the announcement, and what is not
The six defendants are not one kind of business, and the distinction matters for figuring out where you sit.
Four of them — Astra Peptides, Legendary Peptides, Texas Peptides, and Lone Star Peptide — are online vendors that, according to CBS News reporting on the filings, advertise product for research use and sell it without a prescription. That is the gray-market end of the market, and it is not where most legitimate operators live.
The two that should get your attention are the other two. Aesthetic Envy is a California med spa that Lilly alleges promotes retatrutide. Striker Pharmacy is a compounding pharmacy that Lilly alleges has made a version of the drug, and CBS News identified it in a June 2026 investigation as one of several compounding pharmacies producing imitation retatrutide. Those are licensed businesses with real infrastructure, real staff, and, presumably, an internal understanding that they were operating inside the lines.
Alongside the suits, Lilly said it has reported more than 14,000 websites, advertisements, social media posts, and product listings across more than 100 countries to internet service providers, platforms, and e-commerce companies, and that some continue to carry the content anyway. It also issued a direct set of asks: that platforms and marketplaces block this conduct before it reaches consumers, that credit card companies, payment processors, and shipping and logistics carriers cut off the infrastructure the sellers depend on, that regulators and customs agencies coordinate across borders, and that clinicians warn patients. It even published a consumer reporting line through the Lilly Answers Center.
Read that list again from an operator''s perspective. Lilly is not only trying to win six cases. It is trying to make it operationally difficult to run this business at all, by going after payment processing, shipping, and ad distribution. If your program depends on any of those, your risk is not limited to being named in a complaint.
The 200 referrals are the part nobody is discussing
The number that should make people uncomfortable is not six. It is 200.
Lilly said it referred more than 200 individuals and entities to the FDA, the Department of Justice, state attorneys general, law enforcement, and professional licensing boards. It did not publish that list, and it is under no obligation to.
So the honest answer to "who are they?" is that nobody outside Lilly knows, and that is the point worth sitting with. A referral to a state licensing board does not come with a press release. It arrives as a board inquiry months later, addressed to an individual licensee, and by the time it lands it does not look like it has anything to do with Eli Lilly. If you have a medical director, a supervising physician, a PA, or an NP whose name is attached to a retatrutide protocol somewhere, that person could be on a list right now with no way to find out. The six lawsuits are the visible layer. The referrals are the layer that touches individual licenses, and licenses are considerably harder to repair than a business decision.
The legal mechanism, and why a competitor can do this at all
The Federal Food, Drug, and Cosmetic Act contains no private right of action. A competitor cannot sue you for violating the FDCA directly. What a competitor can do is bring federal false advertising and unfair competition claims under the Lanham Act, layer on state unfair competition and false advertising claims, and add trademark claims wherever its brand names are being invoked. The underlying FDCA problem then enters the case as evidence that the marketing was deceptive, rather than as the cause of action itself.
That structure is exactly why the research-use-only label is the center of gravity here. Lilly''s theory, as described in its own announcement, is that these sellers falsely claim their products are for research use when they are actually intended for human use. The disclaimer is not being treated as a defense. It is being treated as the misrepresentation.
Lilly has run this playbook before. In 2023 it sued eight companies across five states over compounded Mounjaro, and followed the next year with additional false advertising filings. What is different now is the molecule. Semaglutide and tirzepatide at least had an approval and a shortage listing to argue about. Retatrutide has neither, which removes most of the defenses a compounder would ordinarily reach for.
Why retatrutide is different from semaglutide and tirzepatide
This is still the most common misunderstanding I hear from clients, so it is worth walking through slowly.
When semaglutide and tirzepatide sat on the FDA shortage list, compounding those molecules had a defined pathway under sections 503A and 503B, and a lot of programs were built on it in good faith. When the shortages resolved, that pathway closed. Retatrutide never had it at all. It has never been approved, so it was never on a shortage list, and it is not an eligible bulk drug substance. The precondition for the exception simply never existed, and the FDA has now said directly, on its own GLP-1 guidance page, that retatrutide and cagrilintide may not be used in compounding.
| Semaglutide / tirzepatide (during shortage) | Retatrutide | |
|---|---|---|
| FDA approval | Approved | Investigational only |
| On FDA shortage list | Yes, at the time | Never |
| Eligible for 503A/503B compounding | Yes, while listed | No |
| Current FDA position | Shortage resolved; pathway closed | May not be used in compounding |
A valid prescription does not repair this. Prescriptive authority is necessary for lawful compounding, but it does not convert an ineligible substance into an eligible one. An operator who ran a compounded semaglutide program during the shortage and then routed the same patients, the same pharmacy, and the same intake flow toward retatrutide has not done a slightly riskier version of what they were doing before. They have done something categorically different, using infrastructure that feels familiar, which is precisely why so many people have walked into it without noticing.
The labeling games are worth understanding too, because they are documented. In warning letters issued in March 2026, the FDA described vendors selling retatrutide under coded product names rather than its own, including one vendor offering products designated GLP1-R, GLP1-S, and GLP1-T, with GLP1-R identified as retatrutide. If a product on your sourcing list is identified by a code rather than a molecule name, that is not a supply chain quirk. That is somebody building deniability into the paperwork, and it will not be your deniability.
The record that existed before this week
None of this arrived without warning, and the paper trail is unusually well documented for a market this young.
The FDA warned health care professionals about compounded retatrutide as early as March 2025, and in June 2026 stated plainly that sales of unapproved retatrutide to consumers are illegal, that it cannot be lawfully compounded, and that research-use-only product is of unknown quality and may be harmful. That same month, the agency issued a wave of 25 warning letters to telehealth companies over allegedly false or misleading promotional claims about compounded GLP-1 products, framed as misbranding under FDCA sections 502(a) and 502(n). The FDA has also reported receiving more than 1,700 adverse event reports tied to compounded semaglutide and tirzepatide as of May 21, 2026.
The CBS News investigation published in June found more than 120 websites selling or promoting retatrutide and at least 50 clinics staffed by licensed physicians and nurse practitioners openly advertising it. After reporters made contact, at least 21 clinics pulled the drug from their sites or changed their language. Others defended the practice, with one physician quoted saying, in effect, that approval looked inevitable so there was no reason to wait. Human exposures to retatrutide reported to U.S. poison centers averaged 95 cases per month in the first four months of 2026, a 265 percent jump from the last four months of 2025.
A parallel Public Citizen review found that the FDA had issued warning letters to 14 retatrutide vendors since December 2024, but that 11 were still advertising the drug or related peptides as of May 2026 and eight were still actively selling. Enforcement had largely stopped at the warning letter stage, because seizures and injunctions require DOJ coordination and resources the agency has not consistently had for this category. As recently as August 8, four days before the filings, CBS reporters found Brooklyn bodegas still displaying posters advertising retatrutide alongside other peptides.
That gap between a clear rule and a thin enforcement pipeline is the space a private plaintiff moves into, and it is the whole reason I kept telling people the manufacturer was the one to watch.
The expanded access program is part of the legal strategy
Nine days before the filings, on August 3, 2026, Lilly confirmed a formal expanded access program for retatrutide, after weeks of physician pressure that followed reporting on a single compassionate-use case granted in April.
The criteria are narrow. Patients must be 18 or older, have refractory obesity despite tolerating the highest approved dose of an existing obesity therapy, carry at least two serious or life-threatening obesity-related complications under active care, and be unable to enroll in a retatrutide trial or a comparable study. Clinicians have said publicly that very few patients will clear that bar, and some have noted that the trial-ineligibility requirement assumes a familiarity with trial sites that most practicing physicians do not have.
The sequencing is what I would pay attention to. Lilly now has a lawful pathway on the record for the genuinely desperate patient, which makes it materially harder for a defendant to argue that the black market exists because sick people had nowhere else to turn. If you are building a litigation strategy, you open the front door before you sue the people climbing through the window.
Where operators are actually exposed, and what to check
If you run a weight loss, longevity, wellness, or aesthetics program, here is the audit I would run this month.
Your compounding pharmacy. Ask directly, in writing, whether they compound or have ever compounded retatrutide, cagrilintide, or any other unapproved molecule, for your patients or for anyone else''s. Get their sourcing list and their API origin. A pharmacy willing to make an ineligible substance for someone else is telling you exactly how it evaluates every other order it fills for you, and Striker Pharmacy is now a named defendant for allegedly doing that.
Your own marketing. Search your site, booking flow, email sequences, SMS campaigns, and every social account for the molecule name and its coded variants. The four vendor defendants were reportedly identified through public advertising, and 21 clinics in the CBS investigation quietly scrubbed their sites once a reporter called. Marketing copy is the easiest artifact in the world for a plaintiff''s investigator to screenshot, and it is usually written by someone who has never sat in one of your compliance conversations.
Every license in the chain. The medical director who signs the protocol, the PA or NP who writes the order, the platform that lists the product, and the entity that collects the money each carry separate exposure. Given the 200 unpublished referrals to licensing boards, this is not a theoretical distribution of risk anymore.
Your structure, if you are in a CPOM state. The California defendant is a med spa, and California is not forgiving toward aesthetics businesses that are casual about who owns the clinical entity and who directs clinical decisions. A civil complaint that draws board attention will not stop at the drug question. Ownership, supervision, medical director oversight, and fee arrangements all surface once someone is already looking at your file. If you are unsure where your state lands, our state-by-state CPOM ownership and oversight map is the fastest way to orient.
Your certificates of analysis. A COA is only worth the lab that issued it and your ability to confirm the lab actually issued it. If nobody on your team has ever picked up the phone to verify one, you do not have a verification process, you have a filing cabinet.
The pattern underneath all of this
An industry that spent years describing itself as operating in unregulated space is finding out that the space was never unregulated, it was only unenforced, and those are not the same thing. The part operators consistently get wrong is assuming that enforcement, when it eventually arrives, will come from the agency everyone has been watching. In practice it has come from the FTC, from state attorneys general, from licensing boards, and now from a manufacturer with a Lanham Act claim, a brand protection budget, and a stated intention to make this the beginning rather than the end.
Compliance is not the binder you assemble when someone knocks. It is the sourcing diligence, the vendor documentation, and the marketing review that keep the unapproved product out of your supply chain before anyone has a reason to knock at all.
How we help
Camino Strategy Group builds and operates the compliance infrastructure behind weight loss, longevity, aesthetics, and telehealth programs. That includes pharmacy and vendor diligence, medical director oversight structures, marketing and claims review, and PC/MSO structures that hold up in CPOM states. If you are reading this and you are not completely certain what your pharmacy is compounding or what your website currently says, that is a review to run now rather than next quarter.
Tell us what you are building and we will map the exposure with you.
References
- Lilly, "Lilly calls on online platforms, payment companies and regulators to shut down the illegal retatrutide black market," August 12, 2026: https://www.prnewswire.com/news-releases/lilly-calls-on-online-platforms-payment-companies-and-regulators-to-shut-down-the-illegal-retatrutide-black-market-302849551.html
- CBS News, "Eli Lilly takes aim at illicit market for its experimental weight-loss drug," August 12, 2026: https://www.cbsnews.com/news/eli-lilly-lawsuits-weight-loss-drug/
- Fierce Pharma, "Lilly takes 6 companies to court for selling retatrutide knockoffs," August 12, 2026: https://www.fiercepharma.com/pharma/lilly-takes-6-companies-court-selling-retatrutide-knockoffs
- Medscape, "Unapproved Retatrutide Use Challenges Clinicians," June 2026: https://www.medscape.com/viewarticle/unapproved-retatrutide-use-challenges-clinicians-2026a1000lqj
- Sheppard Mullin, "FDA''s Focus Returns to Compounding and Telehealth: Another Wave of Warning Letters," June 2026: https://www.sheppard.com/insights/blogs/fdas-focus-returns-to-compounding-and-telehealth-another-wave-of-warning-letters
- FDA, "FDA''s concerns with unapproved GLP-1 drugs used for weight loss": https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
- STAT News, "Eli Lilly to offer retatrutide access given earlier to just one patient," August 3, 2026: https://www.statnews.com/2026/08/03/eli-lilly-retatrutide-mystery-patient-doctors-seek-same-access-their-patients/
- Medscape, "Retatrutide Expanded Access Draws Mixed Clinician Views," August 2026: https://www.medscape.com/viewarticle/retatrutide-expanded-access-draws-mixed-clinician-views-2026a1000qn1
This post summarizes public reporting, publicly announced litigation, and published regulatory statements. The allegations described are allegations. No defendant has been found liable, and nothing here is a legal conclusion about any named entity beyond what the cited sources state. This is general compliance commentary, not legal advice. If you are evaluating your own sourcing, pharmacy relationships, or marketing, have it reviewed against your specific facts.